共 50 条
- [43] RAVULIZUMAB VERSUS ECULIZUMAB IN ADULTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: A PROSPECTIVE ANALYSIS ON THE DEEPNESS OF C5 INHIBITION BASED ON PHARMACOKINETICS/PHARMACODYNAMICS AND BREAKTHROUGH HEMOLYSIS OBSERVED IN TWO PHASE 3 RANDOMIZED, MULTICENTER STUDIES HAEMATOLOGICA, 2019, 104 : 25 - 25
- [49] Use of the oral complement factor B inhibitor iptacopan in patients (pts) with paroxysmal nocturnal hemoglobinuria (PNH) with persistent hemolysis despite anti-C5 therapy: long-term efficacy and safety after stopping eculizumab (ECU) ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 173 - 174